A CEO’s Guide to Increasing Laboratory Valuation: Effective Revenue Cycle and Compliance Management are Critical Success Factors

FREE Special Edition White Paper

Download Your FREE Special Report Today!

Simply Complete The Form Below

There is no doubt that the complexity of laboratory revenue cycle management is unmatched in all of health care. With frequent regulatory and compliance rules changes, ever tightening margins, and a severely weakened economy, it is getting harder and harder for potentially acquirable independent labs to be sure they are not leaving potential profits on the table. The Dark Report is happy to offer our readers a chance to download our recently published White Paper “A CEO’s Guide to Increasing Laboratory Valuation: Effective Revenue Cycle and Compliance Management are Critical Success Factors” at absolutely no charge. This free download will provide readers with a detailed analysis of how laboratories can maximize reimbursement to increase revenue and valuation operating margin.

This free White Paper is also of great value to acquiring labs looking to rapidly realize synergies while quickly growing the top line of acquisition to counter the typical post acquisition decline many labs deal with.

Because of its complex and elusive nature, maximizing laboratory reimbursement has always been an untapped reserve with the ability to greatly increase laboratory valuation. The only way to successfully navigate the financial and regulatory pitfalls of the current landscape, laboratories of all sizes must turn to efficient revenue cycle management (RCM). But in order to increase valuation through maximized reimbursement requires CEOs and CFOs to possess a unified understanding of what the often misunderstood RCM is exactly.

The laboratory industry has been in a state of consolidation for the past 20 years leaving recent zenith of clinical and AP laboratory mergers and acquisitions has left far fewer independent labs than just a decade ago. Frequent regulatory and compliance rules changes, tightening margins, and a severely weakened economy increases the pressure on potentially acquirable labs to find immediate ways to increase top line revenue and valuation operating margin.

On the other side of a transaction, the acquiring lab needs to rapidly realize synergies and quickly grow the top line of the acquisition to offset the typical post acquisition declines.

Despite its complex and elusive nature, maximizing laboratory reimbursement has always been the untapped reserve that leads to increased valuation. In order to successfully navigate the financial and regulatory pitfalls of the current landscape, laboratories of all sizes must turn to revenue cycle management (RCM) as the fastest route to that goal. However, increasing valuation through maximized reimbursement requires CEOs and CFOs to have a unified understanding of what RCM is and is not.

Table of Contents

• Introduction: Revenue Cycle Management in the lab – Page 3

• Chapter One: What are the elements driving lab valuation – Page 5

• Chapter Two: RCM challenges in the lab – Page 10

• Chapter Three: Positively impacting lab valuation metrics through RCM – Page 14

• Chapter Four:

             1) Case Study-LabCorp Acquisition of US Labs – Page 21

             2) Case Study-Parthenon Acquisition of Westcliff Medical Laboratories - Page 25

             3) Case Study-Sonic Healthcare Ltd. Acquisition of Piedmont Medical Laboratories – Page 29

• Chapter Five: Conclusions – Page 34

Appendices

• A-1 About Lâle White – Page 37
• A-2 Links to Billing/Coding/Collection Resources – Page 38
• A-3 About The Dark Intelligence Group, Inc. and THE DARK REPORT – Page 39
• A-4 About XIFIN – Page 40

Terms of Use – Page 41

Contact Information – Page 41

Legal Notices – Page 41